Business
Precigen Reports Fourth Quarter and Full Year 2021 Financial Results
- 2021 clinical milestone objectives successfully accomplished - - Positive clinical data presented across three platforms - UltraCAR-T®, AdenoVerse™,
About this update from Precigen, Inc.
[{"type":"text","content":"- 2021 clinical milestone objectives successfully accomplished -\n - Positive clinical data presented across three platforms - UltraCAR-T®, AdenoVerse™, ActoBiotics™ - and five clinical programs -\n - Public offering to strengthen balance sheet successfully closed while streamlining operations and reducing operating expenses -\n - Concentration now on rapid paths to licensure for programs addressing high unmet patient needs -\n\n\nGERMANTOWN, Md., March 1, 2022 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced fourth quarter and full year 2021 financial results. \n\n \n \n \n \n \n \n\n \n\"In 2021, Precigen was able to demonstrate significant progress in our core therapeutic platforms with indicators of strong early efficacy and favorable safety profiles across each of our most clinically advanced assets,\" said Helen Sabzevari, PhD, President and CEO of Precigen. \"As we advance assets with the most promising paths to licensure, we will continue to focus on strengthening our financial position by continuing to ensure operational efficiency while seeking strategic non-dilutive funding opportunities where appropriate.\" \nKey Business Highlights\nPublic Offering: In January, Precigen closed a public offering of 17,250,000 shares of common stock, which resulted in gross proceeds to Precigen of approximately $129.4 million before deducting the underwriting discount and other offering expenses payable by Precigen; PRGN-3006 UltraCAR-T in Acute Myeloid Leukemia (AML): In 2021, enrollment in the dose escalation phase of the Phase 1/1b PRGN-3006 UltraCAR-T clinical trial for the treatment of patients with relapsed or refractory AML or higher-risk myelodysplastic syndromes (MDS) was completed for both the lymphodepletion and non-lymphodepletion cohorts. Interim data for patients treated in Dose Levels 1-3 of the non-lymphodepletion cohort and Dose Levels 1-2 of the lymphodepletion cohort were presented at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition in December 2021; PRGN-3005 UltraCAR-T in Ovarian Cancer: In 2021, enrollment in the dose escalation phase of the Phase 1/1b clinical trial for the treatment of patients with advanced, recurrent platinum-resistant ova...